<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.retrovirology.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Retrovirology - Latest Articles</title>
        <link>http://www.retrovirology.com</link>
        <description>The latest research articles published by Retrovirology</description>
        <dc:date>2013-05-24T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/54" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/53" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/52" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/51" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/50" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/49" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/48" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/47" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/46" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/10/1/45" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.retrovirology.com/content/10/1/54">
        <title>The frantic play of the concealed HIV envelope cytoplasmic tail</title>
        <description>Lentiviruses have unusually long envelope (Env) cytoplasmic tails, longer than those of other retroviruses. Whereas the Env ectodomain has received much attention, the gp41 cytoplasmic tail (gp41-CT) is one of the least studied parts of the virus. It displays relatively high conservation compared to the rest of Env. It has been long established that the gp41-CT interacts with the Gag precursor protein to ensure Env incorporation into the virion. The gp41-CT contains distinct motifs and domains that mediate both intensive Env intracellular trafficking and interactions with numerous cellular and viral proteins, optimizing viral infectivity. Although they are not fully understood, a multiplicity of interactions between the gp41-CT and cellular factors have been described over the last decade; these interactions illustrate how Env expression and incorporation into virions is a finely tuned process that has evolved to best exploit the host system with minimized genetic information. This review addresses the structure and topology of the gp41-CT of lentiviruses (mainly HIV and SIV), their domains and believed functions. It also considers the cellular and viral proteins that have been described to interact with the gp41-CT, with a particular focus on subtype-related polymorphisms.</description>
        <link>http://www.retrovirology.com/content/10/1/54</link>
                <dc:creator>Eveline Santos da Silva</dc:creator>
                <dc:creator>Martin Mulinge</dc:creator>
                <dc:creator>Danielle Perez Bercoff</dc:creator>
                <dc:source>Retrovirology 2013, null:54</dc:source>
        <dc:date>2013-05-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-54</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-54-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2013-05-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/53">
        <title>The HIV-1 pandemic: does the selective sweep in chimpanzees mirror humankind&apos;s future?</title>
        <description>An HIV-1 infection progresses in most human individuals sooner or later into AIDS, a devastating disease that kills more than a million people worldwide on an annual basis. Nonetheless, certain HIV-1-infected persons appear to act as long-term non-progressors, and elite control is associated with the presence of particular MHC class I allotypes such as HLA-B*27 or -B*57. The HIV-1 pandemic in humans arose from the cross-species transmission of SIVcpz originating from chimpanzees. Chimpanzees, however, appear to be relatively resistant to developing AIDS after HIV-1/SIVcpz infection. Mounting evidence illustrates that, in the distant past, chimpanzees experienced a selective sweep resulting in a severe reduction of their MHC class I repertoire. This was most likely caused by an HIV-1/SIV-like retrovirus, suggesting that chimpanzees may have experienced long-lasting host-virus relationships with SIV-like viruses. Hence, if natural selection is allowed to follow its course, prospects for the human population may look grim, thus underscoring the desperate need for an effective vaccine.</description>
        <link>http://www.retrovirology.com/content/10/1/53</link>
                <dc:creator>Natasja de Groot</dc:creator>
                <dc:creator>Ronald Bontrop</dc:creator>
                <dc:source>Retrovirology 2013, null:53</dc:source>
        <dc:date>2013-05-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-53</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-53-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>53</prism:startingPage>
        <prism:publicationDate>2013-05-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/52">
        <title>Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells</title>
        <description>Background:
Human T-cell leukemia virus type-1 (HTLV-1) is the causative retrovirus of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 gene expression is maintained at low levels in vivo by unknown mechanisms. A combination therapy of interferon-alpha (IFN-alpha) and zidovudin (AZT) shows therapeutic effects in ATL patients, although its mechanism is also obscure. We previously found that viral gene expression in IL-2-dependent HTLV-1-infected T-cells (ILTs) derived from ATL patients was markedly suppressed by stromal cells through a type I IFN response. Here, we investigated the effects of IFN-alpha with or without AZT on viral gene expression and cell growth in ILTs.
Results:
ILTs expressed variable but lower amounts of HTLV-1 Tax protein than HTLV-1-transformed HUT102 cells. Following the addition of IFN-alpha, the amounts of HTLV-1 p19 in the supernatants of these cells decreased in three days, while HTLV-1 gene expression decreased only in ILTs but not HUT102 cells. IFN-alpha also suppressed the spontaneous HTLV-1 induction in primary ATL cells cultured for 24 h. A time course study using ILTs revealed that the levels of intracellular Tax proteins decreased in the first 24 h after addition of IFN-alpha, before the reduction in HTLV-1 mRNA levels. The initial decreases of Tax protein following IFN-alpha treatment were observed in 6 of 7 ILT lines tested, although the reduction rates varied among ILT lines. An RNA-dependent protein kinase (PKR)-inhibitor reversed IFN-mediated suppression of Tax in ILTs. IFN-alpha also induced cell cycle arrest at the G0/G1 phase and suppressed NF-kappaB activities in these cells. AZT alone did not affect HTLV-1 gene expression, cell viability or NF-kappaB activities. AZT combined with IFN-alpha markedly induced cell apoptosis associated with phosphorylation of p53 and induction of p53-responsive genes in ILTs.
Conclusions:
IFN-alpha suppressed HTLV-1 gene expression at least through a PKR-mediated mechanism, and also induced cell cycle arrest in ILTs. In combination with AZT, IFN-alpha further induced p53 signaling and cell apoptosis in these cells. These findings suggest that HTLV-1-infected cells at an IL-2-dependent stage retain susceptibility to type I IFN-mediated regulation of viral expression, and partly explain how AZT/IFN-alpha produces therapeutic effects in ATL.</description>
        <link>http://www.retrovirology.com/content/10/1/52</link>
                <dc:creator>Shuichi Kinpara</dc:creator>
                <dc:creator>Mami Kijiyama</dc:creator>
                <dc:creator>Ayako Takamori</dc:creator>
                <dc:creator>Atsuhiko Hasegawa</dc:creator>
                <dc:creator>Amane Sasada</dc:creator>
                <dc:creator>Takao Masuda</dc:creator>
                <dc:creator>Yuetsu Tanaka</dc:creator>
                <dc:creator>Atae Utsunomiya</dc:creator>
                <dc:creator>Mari Kannagi</dc:creator>
                <dc:source>Retrovirology 2013, null:52</dc:source>
        <dc:date>2013-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-52</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-52-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>52</prism:startingPage>
        <prism:publicationDate>2013-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/51">
        <title>Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis</title>
        <description>Background:
OX40 is a member of the tumor necrosis factor receptor family that is expressed primarily on activated CD4+ T cells and promotes the development of effector and memory T cells. Although OX40 has been reported to be a target gene of human T-cell leukemia virus type-1 (HTLV-1) viral transactivator Tax and is overexpressed in vivo in adult T-cell leukemia (ATL) cells, an association between OX40 and HTLV-1-associated inflammatory disorders, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), has not yet been established. Moreover, because abrogation of OX40 signals ameliorates chronic inflammation in animal models of autoimmune disease, novel monoclonal antibodies against OX40 may offer a potential treatment for HTLV-1-associated diseases such as ATL and HAM/TSP.
Results:
In this study, we showed that OX40 was specifically expressed in CD4+ T cells naturally infected with HTLV-1 that have the potential to produce pro-inflammatory cytokines along with Tax expression. We also showed that OX40 was overexpressed in spinal cord infiltrating mononuclear cells in a clinically progressive HAM/TSP patient with a short duration of illness. The levels of the soluble form of OX40 (sOX40) in the cerebrospinal fluid (CSF) from chronic progressive HAM/TSP patients or from patients with other inflammatory neurological diseases (OINDs) were not different. In contrast, sOX40 levels in the CSF of rapidly progressing HAM/TSP patients were higher than those in the CSF from patients with OINDs, and these patients showed higher sOX40 levels in the CSF than in the plasma. When our newly produced monoclonal antibody against OX40 was added to peripheral blood mononuclear cells in culture, HTLV-1-infected T cells were specifically removed by a mechanism that depends on antibody-dependent cellular cytotoxicity.
Conclusions:
Our study identified OX40 as a key molecule and biomarker for rapid progression of HAM/TSP. Furthermore, blocking OX40 may have potential in therapeutic intervention for HAM/TSP.</description>
        <link>http://www.retrovirology.com/content/10/1/51</link>
                <dc:creator>Mineki Saito</dc:creator>
                <dc:creator>Reiko Tanaka</dc:creator>
                <dc:creator>Shiho Arishima</dc:creator>
                <dc:creator>Toshio Matsuzaki</dc:creator>
                <dc:creator>Satoshi Ishihara</dc:creator>
                <dc:creator>Takashi Tokashiki</dc:creator>
                <dc:creator>Yusuke Ohya</dc:creator>
                <dc:creator>Hiroshi Takashima</dc:creator>
                <dc:creator>Fujio Umehara</dc:creator>
                <dc:creator>Shuji Izumo</dc:creator>
                <dc:creator>Yuetsu Tanaka</dc:creator>
                <dc:source>Retrovirology 2013, null:51</dc:source>
        <dc:date>2013-05-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-51</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-51-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>51</prism:startingPage>
        <prism:publicationDate>2013-05-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/50">
        <title>High level of susceptibility to human TRIM5alpha conferred by HIV-2 capsid sequences</title>
        <description>Background:
HIV-2, which was transmitted to humans from a distant primate species (sooty mangabey), differs remarkably from HIV-1 in its infectivity, transmissibility and pathogenicity. We have tested the possibility that a greater susceptibility of HIV-2 capsid (CA) to the human restriction factor TRIM5alpha (hTRIM5alpha) could contribute to these differences.
Results:
We constructed recombinant clones expressing CA from a variety of HIV-2 viruses in the context of HIV-1 NL4-3-luciferase. CA sequences were amplified from the plasma of HIV-2 infected patients, including 8 subtype A and 7 subtype B viruses. CA from 6 non-epidemic HIV-2 subtypes, 3 HIV-2 CRF01_AB recombinants and 4 SIVsmm viruses were also tested. Susceptibility to hTRIM5alpha was measured by comparing single-cycle infectivity in human target cells expressing hTRIM5alpha to that measured in cells in which hTRIM5alpha activity was inhibited by overexpression of hTRIM5gamma.The insertion of HIV-2 CA sequences in the context of HIV-1 did not affect expression and maturation of the HIV-2 CA protein. The level of susceptibility hTRIM5alpha expressed by viruses carrying HIV-2 CA sequences was up to 9-fold higher than that of HIV-1 NL4-3 and markedly higher than a panel of primary HIV-1 CA sequences. This phenotype was found both for viruses carrying CA from primary HIV-2 sequences and viruses carrying CA from laboratory-adapted HIV-2 clones. High hTRIM5alpha susceptibility was found in all HIV-2 subtypes. In this series of viruses, susceptibility to hTRIM5alpha was not significantly affected by the presence of a proline at position 119 or by the number of prolines at positions 119, 159 or 178 in HIV-2 CA. No significant correlation was found between HIV-2 viremia and sensitivity to hTRIM5alpha.
Conclusions:
HIV-2 capsid sequences expressed high levels of susceptibility to hTRIM5alpha. This property, common to all HIV-2 sequences tested, may contribute in part to the lower replication and pathogenicity of this virus in humans.</description>
        <link>http://www.retrovirology.com/content/10/1/50</link>
                <dc:creator>Junko Takeuchi</dc:creator>
                <dc:creator>Benjamin Perche</dc:creator>
                <dc:creator>Julie Migraine</dc:creator>
                <dc:creator>Séverine Mercier-Delarue</dc:creator>
                <dc:creator>Diane Ponscarme</dc:creator>
                <dc:creator>François Simon</dc:creator>
                <dc:creator>François Clavel</dc:creator>
                <dc:creator>Béatrice Labrosse</dc:creator>
                <dc:source>Retrovirology 2013, null:50</dc:source>
        <dc:date>2013-05-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-50</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-50-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>50</prism:startingPage>
        <prism:publicationDate>2013-05-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/49">
        <title>Within-host and between-host evolutionary rates across the HIV-1 genome</title>
        <description>Background:
HIV evolves rapidly at the epidemiological level but also at the within-host level. The virus&apos; within-host evolutionary rates have been argued to be much higher than its between-host evolutionary rates. However, this conclusion relies on analyses of a short portion of the virus envelope gene. Here, we study in detail these evolutionary rates across the HIV genome.
Results:
We build phylogenies using a relaxed molecular clock assumption to estimate evolutionary rates in different regions of the HIV genome. We find that these rates vary strongly across the HIV genome, with higher rates in the envelope gene (env). Within-host evolutionary rates are consistently higher than between-host rates throughout the HIV genome. This difference is significantly more pronounced in env. Finally, we find weak differences between overlapping and non-overlapping regions.
Conclusions:
We provide a genome-wide overview of the differences in the HIV rates of molecular evolution at the within- and between-host levels. Contrary to hepatitis C virus, where differences are only located in the envelope gene, within-host evolutionary rates are higher than between-host evolutionary rates across the whole HIV genome. This supports the hypothesis that HIV strains that are less adapted to the host have an advantage during transmission. The most likely mechanism for this is storage and then preferential transmission of viruses in latent T-cells. These results shed a new light on the role of the transmission bottleneck in the evolutionary dynamics of HIV.</description>
        <link>http://www.retrovirology.com/content/10/1/49</link>
                <dc:creator>Samuel Alizon</dc:creator>
                <dc:creator>Christophe Fraser</dc:creator>
                <dc:source>Retrovirology 2013, null:49</dc:source>
        <dc:date>2013-05-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-49</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-49-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2013-05-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/48">
        <title>Platelet activation suppresses HIV-1 infection of T cells</title>
        <description>Background:
Platelets, anucleate cell fragments abundant in human blood, can capture HIV-1 and platelet counts have been associated with viral load and disease progression. However, the impact of platelets on HIV-1 infection of T cells is unclear.
Results:
We found that platelets suppress HIV-1 spread in co-cultured T cells in a concentration-dependent manner. Platelets containing granules inhibited HIV-1 spread in T cells more efficiently than degranulated platelets, indicating that the granule content might exert antiviral activity. Indeed, supernatants from activated and thus degranulated platelets suppressed HIV-1 infection. Infection was inhibited at the stage of host cell entry and inhibition was independent of the viral strain or coreceptor tropism. In contrast, blockade of HIV-2 and SIV entry was less efficient. The chemokine CXCL4, a major component of platelet granules, blocked HIV-1 entry and neutralization of CXCL4 in platelet supernatants largely abrogated their anti-HIV-1 activity.
Conclusions:
Release of CXCL4 by activated platelets inhibits HIV-1 infection of adjacent T cells at the stage of virus entry. The inhibitory activity of platelet-derived CXCL4 suggests a role of platelets in the defense against infection by HIV-1 and potentially other pathogens.</description>
        <link>http://www.retrovirology.com/content/10/1/48</link>
                <dc:creator>Theodros Solomon Tsegaye</dc:creator>
                <dc:creator>Kerstin Gnirß</dc:creator>
                <dc:creator>Niels Rahe-Meyer</dc:creator>
                <dc:creator>Miriam Kiene</dc:creator>
                <dc:creator>Annika Krämer-Kühl</dc:creator>
                <dc:creator>Georg Behrens</dc:creator>
                <dc:creator>Jan Münch</dc:creator>
                <dc:creator>Stefan Pöhlmann</dc:creator>
                <dc:source>Retrovirology 2013, null:48</dc:source>
        <dc:date>2013-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-48</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-48-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>48</prism:startingPage>
        <prism:publicationDate>2013-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/47">
        <title>Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats</title>
        <description>Background:
Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia and tropical spastic paraparesis. HTLV-1 encodes transactivator protein Tax that interacts with various cellular factors to modulate transcription and other biological functions. Additional cellular mediators of Tax-mediated transcriptional activation of HTLV-1 long terminal repeats (LTR) remain to be identified and characterized.
Results:
In this study, we investigated the regulatory role of group I p21-activated kinases (Paks) in Tax-induced LTR activation. Both wild-type and kinase-dead mutants of Pak3 were capable of potentiating the activity of Tax to activate LTR transcription. The effect of Paks on the LTR was attributed to the N-terminal regulatory domain and required the action of CREB, CREB-regulating transcriptional coactivators (CRTCs) and p300/CREB-binding protein. Paks physically associated with Tax and CRTCs. Paks were recruited to the LTR in the presence of Tax. siRNAs against either Pak1 or Pak3 prevented the interaction of Tax with CRTC1 and the recruitment of Tax to the LTR. These siRNAs also inhibited LTR-dependent transcription in HTLV-1-transformed MT4 cells and in cells transfected with an infectious clone of HTLV-1.
Conclusion:
Group I Paks augment Tax-mediated transcriptional activation of HTLV-1 LTR in a kinase-independent manner.</description>
        <link>http://www.retrovirology.com/content/10/1/47</link>
                <dc:creator>Ching-Ping Chan</dc:creator>
                <dc:creator>Yeung-Tung Siu</dc:creator>
                <dc:creator>Kin-Hang Kok</dc:creator>
                <dc:creator>Yick-Pang Ching</dc:creator>
                <dc:creator>Hei-Man Tang</dc:creator>
                <dc:creator>Dong-Yan Jin</dc:creator>
                <dc:source>Retrovirology 2013, null:47</dc:source>
        <dc:date>2013-04-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-47</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-47-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>47</prism:startingPage>
        <prism:publicationDate>2013-04-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/46">
        <title>The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6</title>
        <description>Background:
Expression of the cellular karyopherin TNPO3/transportin-SR2/Tnp3 is necessary for HIV-1 infection. Depletion of TNPO3 expression in mammalian cells inhibits HIV-1 infection after reverse transcription but prior to integration.
Results:
This work explores the role of cleavage and polyadenylation specificity factor subunit 6 (CPSF6) in the ability of TNPO3-depleted cells to inhibit HIV-1 infection. Our findings showed that depletion of TNPO3 expression inhibits HIV-1 infection, while the simultaneous depletion of TNPO3 and CPSF6 expression rescues HIV-1 infection. Several experiments to understand the rescue of infectivity by CPSF6 were performed. Our experiments revealed that the HIV-1 capsid binding ability of the endogenously expressed CPSF6 from TNPO3-depleted cells does not change when compared to CPSF6 from wild type cells. In agreement with our previous results, depletion of TNPO3 did not change the nuclear localization of CPSF6. Studies on the formation of 2-LRT circles during HIV-1 infection revealed that TNPO3-depleted cells are impaired in the integration process or exhibit a defect in the formation of 2-LTR circles. To understand whether the cytosolic fraction of CPSF6 is responsible for the inhibition of HIV-1 in TNPO3-depleted cells, we tested the ability of a cytosolic full-length CPSF6 to block HIV-1 infection. These results demonstrated that overexpression of a cytosolic full-length CPSF6 blocks HIV-1 infection at the nuclear import step. Fate of the capsid assays revealed that cytosolic expression of CPSF6 enhances stability of the HIV-1 core during infection.
Conclusions:
These results suggested that inhibition of HIV-1 by TNPO3-depleted cells requires CPSF6.</description>
        <link>http://www.retrovirology.com/content/10/1/46</link>
                <dc:creator>Thomas Fricke</dc:creator>
                <dc:creator>Jose Valle-Casuso</dc:creator>
                <dc:creator>Tommy White</dc:creator>
                <dc:creator>Alberto Brandariz-Nuñez</dc:creator>
                <dc:creator>William Bosche</dc:creator>
                <dc:creator>Natalia Reszka</dc:creator>
                <dc:creator>Robert Gorelick</dc:creator>
                <dc:creator>Felipe Diaz-Griffero</dc:creator>
                <dc:source>Retrovirology 2013, null:46</dc:source>
        <dc:date>2013-04-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-46</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-46-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>46</prism:startingPage>
        <prism:publicationDate>2013-04-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/10/1/45">
        <title>An N-terminal domain helical motif of Prototype Foamy Virus Gag with dual functions essential for particle egress and viral infectivity</title>
        <description>Background:
Foamy viruses (FVs) have developed a unique budding strategy within the retrovirus family. FV release requires co-expression and a highly specific interaction between capsid (Gag) and glycoprotein (Env), which cannot be complemented by heterologous Env proteins. The interaction domain in FV Env has been mapped in greater detail and resides mainly in the N-terminal tip of the cytoplasmic domain of the Env leader peptide subunit. In contrast, the corresponding domain within Gag is less well defined. Previous investigations suggest that it is located within the N-terminal part of the protein.
Results:
Here we characterized additional Gag interaction determinants of the prototype FV (PFV) isolate using a combination of particle release, GST pull-down and single cycle infectivity analysis assays. Our results demonstrate that a minimal PFV Gag protein comprising the N-terminal 129 aa was released into the supernatant, whereas proteins lacking this domain failed to do so. Fine mapping of domains within the N-terminus of PFV Gag revealed that the N-terminal 10 aa of PFV Gag were dispensable for viral replication. In contrast, larger deletions or structurally deleterious point mutations in C-terminally adjacent sequences predicted to harbor a helical region abolished particle egress and Gag -- Env protein interaction. Pull-down assays, using proteins of mammalian and prokaryotic origin, support the previous hypothesis of a direct interaction of both PFV proteins without requirement for cellular cofactors and suggest a potential direct contact of Env through this N-terminal Gag domain. Furthermore, analysis of point mutants within this domain in context of PFV vector particles indicates additional particle release-independent functions for this structure in viral replication by directly affecting virion infectivity.
Conclusions:
Thus, our results demonstrate not only a critical function of an N-terminal PFV Gag motif for the essential capsid - glycoprotein interaction required for virus budding but also point out additional functions that affect virion infectivity.</description>
        <link>http://www.retrovirology.com/content/10/1/45</link>
                <dc:creator>Juliane Reh</dc:creator>
                <dc:creator>Annett Stange</dc:creator>
                <dc:creator>Anne Götz</dc:creator>
                <dc:creator>Marlene Rönitz</dc:creator>
                <dc:creator>Arend Große</dc:creator>
                <dc:creator>Dirk Lindemann</dc:creator>
                <dc:source>Retrovirology 2013, null:45</dc:source>
        <dc:date>2013-04-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-10-45</dc:identifier>
                                <prism:require>/content/figures/1742-4690-10-45-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>45</prism:startingPage>
        <prism:publicationDate>2013-04-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
